Specialty Business Services
Compare Stocks
5 / 10Stock Comparison
QUAD vs ESLT vs LHX vs SRPT vs RTX
Revenue, margins, valuation, and 5-year total return — side by side.
Aerospace & Defense
Aerospace & Defense
Biotechnology
Aerospace & Defense
QUAD vs ESLT vs LHX vs SRPT vs RTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Specialty Business Services | Aerospace & Defense | Aerospace & Defense | Biotechnology | Aerospace & Defense |
| Market Cap | $400M | $36.92B | $56.26B | $2.18B | $238.07B |
| Revenue (TTM) | $2.37B | $8.07B | $22.48B | $2.18B | $90.37B |
| Net Income (TTM) | $27M | $544M | $1.73B | $65M | $7.26B |
| Gross Margin | 18.5% | 24.4% | 24.5% | 34.4% | 20.2% |
| Operating Margin | 5.0% | 8.5% | 10.0% | -1.9% | 10.4% |
| Forward P/E | 6.3x | 57.3x | 26.0x | 6.9x | 25.5x |
| Total Debt | $444M | $965M | $10.44B | $1.04B | $39.51B |
| Cash & Equiv. | $63M | $635M | $1.07B | $801M | $7.43B |
QUAD vs ESLT vs LHX vs SRPT vs RTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Quad/Graphics, Inc. (QUAD) | 100 | 268.8 | +168.8% |
| Elbit Systems Ltd. (ESLT) | 100 | 564.2 | +464.2% |
| L3Harris Technologi… (LHX) | 100 | 151.0 | +51.0% |
| Sarepta Therapeutic… (SRPT) | 100 | 13.7 | -86.3% |
| RTX Corporation (RTX) | 100 | 274.0 | +174.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: QUAD vs ESLT vs LHX vs SRPT vs RTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
QUAD is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (6.3x vs 25.5x)
- 3.8% yield, 2-year raise streak, vs LHX's 1.6%, (1 stock pays no dividend)
ESLT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 23.9%, EPS growth 71.7%, 3Y rev CAGR 17.8%
- 7.4% 10Y total return vs LHX's 346.1%
- Lower volatility, beta 0.35, Low D/E 23.4%, current ratio 1.29x
- 23.9% revenue growth vs QUAD's -9.4%
LHX is the clearest fit if your priority is income & stability and valuation efficiency.
- Dividend streak 6 yrs, beta 0.39, yield 1.6%
- PEG 2.48 vs ESLT's 3.48
- Beta 0.39, yield 1.6%, current ratio 1.19x
Among these 5 stocks, SRPT doesn't own a clear edge in any measured category.
RTX ranks third and is worth considering specifically for quality.
- 8.0% margin vs QUAD's 1.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.9% revenue growth vs QUAD's -9.4% | |
| Value | Lower P/E (6.3x vs 25.5x) | |
| Quality / Margins | 8.0% margin vs QUAD's 1.2% | |
| Stability / Safety | Beta 0.35 vs SRPT's 2.02, lower leverage | |
| Dividends | 3.8% yield, 2-year raise streak, vs LHX's 1.6%, (1 stock pays no dividend) | |
| Momentum (1Y) | +92.7% vs SRPT's -43.4% | |
| Efficiency (ROA) | 4.5% ROA vs SRPT's 1.9%, ROIC 12.8% vs -31.4% |
QUAD vs ESLT vs LHX vs SRPT vs RTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
QUAD vs ESLT vs LHX vs SRPT vs RTX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
QUAD leads in 2 of 6 categories
ESLT leads 1 • LHX leads 0 • SRPT leads 0 • RTX leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — LHX and SRPT and RTX each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RTX is the larger business by revenue, generating $90.4B annually — 41.4x SRPT's $2.2B. RTX is the more profitable business, keeping 8.0% of every revenue dollar as net income compared to QUAD's 1.2%. On growth, LHX holds the edge at +11.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.4B | $8.1B | $22.5B | $2.2B | $90.4B |
| EBITDAEarnings before interest/tax | $196M | $857M | $3.3B | -$6M | $13.8B |
| Net IncomeAfter-tax profit | $27M | $544M | $1.7B | $65M | $7.3B |
| Free Cash FlowCash after capex | $44M | $564M | $2.6B | $107M | $8.4B |
| Gross MarginGross profit ÷ Revenue | +18.5% | +24.4% | +24.5% | +34.4% | +20.2% |
| Operating MarginEBIT ÷ Revenue | +5.0% | +8.5% | +10.0% | -1.9% | +10.4% |
| Net MarginNet income ÷ Revenue | +1.2% | +6.7% | +7.7% | +3.0% | +8.0% |
| FCF MarginFCF ÷ Revenue | +1.9% | +7.0% | +11.5% | +4.9% | +9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.7% | +11.8% | +11.9% | -1.9% | +8.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +18.2% | +79.5% | +33.3% | +162.6% | +32.5% |
Valuation Metrics
QUAD leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 14.2x trailing earnings, QUAD trades at a 78% valuation discount to ESLT's 64.5x P/E. Adjusting for growth (PEG ratio), LHX offers better value at 3.37x vs ESLT's 3.92x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $400M | $36.9B | $56.3B | $2.2B | $238.1B |
| Enterprise ValueMkt cap + debt − cash | $781M | $37.2B | $65.6B | $2.4B | $270.1B |
| Trailing P/EPrice ÷ TTM EPS | 14.19x | 64.47x | 35.31x | -2.92x | 35.64x |
| Forward P/EPrice ÷ next-FY EPS est. | 6.30x | 57.26x | 26.00x | 6.93x | 25.54x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.92x | 3.37x | — | — |
| EV / EBITDAEnterprise value multiple | 3.96x | 39.55x | 19.20x | — | 20.96x |
| Price / SalesMarket cap ÷ Revenue | 0.17x | 4.30x | 2.57x | 0.99x | 2.69x |
| Price / BookPrice ÷ Book value/share | 2.97x | 9.03x | 2.89x | 1.91x | 3.57x |
| Price / FCFMarket cap ÷ FCF | 7.90x | 61.70x | 20.98x | — | 29.98x |
Profitability & Efficiency
QUAD leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
QUAD delivers a 25.0% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $5 for SRPT. ESLT carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to QUAD's 3.45x. On the Piotroski fundamental quality scale (0–9), LHX scores 9/9 vs SRPT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +25.0% | +14.1% | +8.9% | +4.9% | +10.9% |
| ROA (TTM)Return on assets | +2.2% | +4.5% | +4.2% | +1.9% | +4.3% |
| ROICReturn on invested capital | +17.9% | +12.8% | +5.4% | -31.4% | +6.7% |
| ROCEReturn on capital employed | +19.3% | +12.2% | +6.4% | -24.0% | +7.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 8 | 9 | 4 | 8 |
| Debt / EquityFinancial leverage | 3.45x | 0.23x | 0.53x | 0.91x | 0.59x |
| Net DebtTotal debt minus cash | $381M | $330M | $9.4B | $238M | $32.1B |
| Cash & Equiv.Liquid assets | $63M | $635M | $1.1B | $801M | $7.4B |
| Total DebtShort + long-term debt | $444M | $965M | $10.4B | $1.0B | $39.5B |
| Interest CoverageEBIT ÷ Interest expense | 2.11x | 4.92x | 4.41x | -14.00x | 5.58x |
Total Returns (Dividends Reinvested)
ESLT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ESLT five years ago would be worth $58,629 today (with dividends reinvested), compared to $2,789 for SRPT. Over the past 12 months, ESLT leads with a +92.7% total return vs SRPT's -43.4%. The 3-year compound annual growth rate (CAGR) favors ESLT at 61.1% vs SRPT's -45.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +33.6% | +34.5% | -0.7% | -2.4% | -5.2% |
| 1-Year ReturnPast 12 months | +44.4% | +92.7% | +40.4% | -43.4% | +40.8% |
| 3-Year ReturnCumulative with dividends | +197.1% | +318.0% | +68.4% | -83.6% | +93.0% |
| 5-Year ReturnCumulative with dividends | +158.1% | +486.3% | +47.8% | -72.1% | +120.1% |
| 10-Year ReturnCumulative with dividends | -23.3% | +737.2% | +346.1% | +18.0% | +234.7% |
| CAGR (3Y)Annualised 3-year return | +43.8% | +61.1% | +19.0% | -45.3% | +24.5% |
Risk & Volatility
Evenly matched — QUAD and ESLT each lead in 1 of 2 comparable metrics.
Risk & Volatility
ESLT is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than SRPT's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. QUAD currently trades 88.7% from its 52-week high vs SRPT's 47.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.03x | 0.35x | 0.39x | 2.02x | 0.51x |
| 52-Week HighHighest price in past year | $8.64 | $1016.00 | $379.23 | $44.14 | $214.50 |
| 52-Week LowLowest price in past year | $5.01 | $369.60 | $214.10 | $10.42 | $126.03 |
| % of 52W HighCurrent price vs 52-week peak | +88.7% | +78.2% | +79.4% | +47.1% | +82.4% |
| RSI (14)Momentum oscillator 0–100 | 50.6 | 43.6 | 24.2 | 63.4 | 37.3 |
| Avg Volume (50D)Average daily shares traded | 231K | 165K | 1.4M | 3.0M | 5.3M |
Analyst Outlook
Evenly matched — QUAD and LHX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: QUAD as "Buy", ESLT as "Hold", LHX as "Buy", SRPT as "Buy", RTX as "Buy". Consensus price targets imply 27.2% upside for RTX (target: $225) vs -33.2% for ESLT (target: $531). For income investors, QUAD offers the higher dividend yield at 3.77% vs ESLT's 0.32%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $8.00 | $531.00 | $352.25 | $24.63 | $224.89 |
| # AnalystsCovering analysts | 7 | 6 | 32 | 54 | 26 |
| Dividend YieldAnnual dividend ÷ price | +3.8% | +0.3% | +1.6% | — | +1.5% |
| Dividend StreakConsecutive years of raises | 2 | 1 | 6 | — | 4 |
| Dividend / ShareAnnual DPS | $0.29 | $2.58 | $4.79 | — | $2.63 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.0% | 0.0% | +2.1% | +1.1% | +0.0% |
QUAD leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). ESLT leads in 1 (Total Returns). 3 tied.
QUAD vs ESLT vs LHX vs SRPT vs RTX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is QUAD or ESLT or LHX or SRPT or RTX a better buy right now?
For growth investors, Elbit Systems Ltd.
(ESLT) is the stronger pick with 23. 9% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). Quad/Graphics, Inc. (QUAD) offers the better valuation at 14. 2x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate Quad/Graphics, Inc. (QUAD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — QUAD or ESLT or LHX or SRPT or RTX?
On trailing P/E, Quad/Graphics, Inc.
(QUAD) is the cheapest at 14. 2x versus Elbit Systems Ltd. at 64. 5x. On forward P/E, Quad/Graphics, Inc. is actually cheaper at 6. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: L3Harris Technologies, Inc. wins at 2. 48x versus Elbit Systems Ltd. 's 3. 48x.
03Which is the better long-term investment — QUAD or ESLT or LHX or SRPT or RTX?
Over the past 5 years, Elbit Systems Ltd.
(ESLT) delivered a total return of +486. 3%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: ESLT returned +737. 2% versus QUAD's -23. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — QUAD or ESLT or LHX or SRPT or RTX?
By beta (market sensitivity over 5 years), Elbit Systems Ltd.
(ESLT) is the lower-risk stock at 0. 35β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 479% more volatile than ESLT relative to the S&P 500. On balance sheet safety, Elbit Systems Ltd. (ESLT) carries a lower debt/equity ratio of 23% versus 3% for Quad/Graphics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — QUAD or ESLT or LHX or SRPT or RTX?
By revenue growth (latest reported year), Elbit Systems Ltd.
(ESLT) is pulling ahead at 23. 9% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: Quad/Graphics, Inc. grew EPS 150. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — QUAD or ESLT or LHX or SRPT or RTX?
RTX Corporation (RTX) is the more profitable company, earning 7.
6% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LHX leads at 10. 0% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is QUAD or ESLT or LHX or SRPT or RTX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, L3Harris Technologies, Inc. (LHX) is the more undervalued stock at a PEG of 2. 48x versus Elbit Systems Ltd. 's 3. 48x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Quad/Graphics, Inc. (QUAD) trades at 6. 3x forward P/E versus 57. 3x for Elbit Systems Ltd. — 51. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RTX: 27. 2% to $224. 89.
08Which pays a better dividend — QUAD or ESLT or LHX or SRPT or RTX?
In this comparison, QUAD (3.
8% yield), LHX (1. 6% yield), RTX (1. 5% yield), ESLT (0. 3% yield) pay a dividend. SRPT does not pay a meaningful dividend and should not be held primarily for income.
09Is QUAD or ESLT or LHX or SRPT or RTX better for a retirement portfolio?
For long-horizon retirement investors, L3Harris Technologies, Inc.
(LHX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), 1. 6% yield, +346. 1% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LHX: +346. 1%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between QUAD and ESLT and LHX and SRPT and RTX?
These companies operate in different sectors (QUAD (Industrials) and ESLT (Industrials) and LHX (Industrials) and SRPT (Healthcare) and RTX (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: QUAD is a small-cap deep-value stock; ESLT is a mid-cap high-growth stock; LHX is a mid-cap quality compounder stock; SRPT is a small-cap high-growth stock; RTX is a large-cap quality compounder stock. QUAD, LHX, RTX pay a dividend while ESLT, SRPT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.